Advertisement
Advertisement
U.S. markets open in 6 hours 47 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Sirona Biochem Corp. (SBM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1650-0.0200 (-10.81%)
At close: 03:06PM EDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1850
Open0.1700
Bid0.1600 x 0
Ask0.1850 x 0
Day's Range0.1650 - 0.1700
52 Week Range0.1400 - 0.3500
Volume72,005
Avg. Volume36,639
Market Cap41.47M
Beta (5Y Monthly)-0.68
PE Ratio (TTM)N/A
EPS (TTM)-0.0160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 27, 2006
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SBM.V

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Sirona Biochem Corporate Update

      VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an outlook of our ongoing corporate development. On June 13th we announced that we had successfully completed an exclusive global license for TFC-1067 and related family of compounds with Allergan Aesthetics (an AbbVie company). This deal represents a major milestone for Sirona and one we ha

    • GlobeNewswire

      Sirona Biochem Contracts WuXi AppTec to Manufacture Revolutionary Anti-Aging/Anti-Wrinkle Compound for Clinical Trial

      VANCOUVER, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that it has signed an agreement with Contract Manufacturing Organization (CMO) WuXi AppTec (“WuXi”), Shanghai, for the small-scale production of TFC-1326, a powerful active against the aging effects on skin. Years of groundbreaking research by Sirona’s team of scientists at TFChem has shown in preclinical studies that TFC-1326 has the potentia

    • GlobeNewswire

      Former Bayer Senior Executive Joins Sirona Biochem Advisory Board

      VANCOUVER, British Columbia, June 20, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that Dr. Wolfgang Bieber will join Sirona Biochem’s Advisory Board and act as a consultant to the Board of Directors with immediate effect. Dr. Wolfgang Bieber brings to Sirona Biochem 30 years of experience from his career at BAYER AG, a global pharmaceutical and agrochemical company with sales of US$52 billion and more than 100,000 employees

    Advertisement
    Advertisement